Drugs / AZD4063
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07241104 | Dec 2025 → Nov 2027 expected | dilated cardiomyopathy | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4063 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07241104 ↗ |
| Route | Subcutaneous | “via subcutaneous route of administration” NCT07241104 ↗ |